Center of Excellence for Rare Metabolic Diseases, Interdisciplinary Center of Metabolism: Endocrinology, Diabetes and Metabolism, University-Medicine Berlin, Campus Virchow-Klinikum, Augustenburger Platz 1, 13352, Berlin, Germany.
Orphanet J Rare Dis. 2019 Jun 27;14(1):158. doi: 10.1186/s13023-019-1130-5.
In 2009 the European Commission called for National action plans (NAP) to improve the care for persons with rare diseases. Germany set up a NAP in 2013 suggesting a three-tiered structure of co-operating centers (CC), centers of excellence (CE) and reference centers (CR). Since then CEs and CRs were organized in the framework of university hospitals. However, realization of CCs taking into account the requirements of the NAP has been slow. We therefore set-up a 12-months program to initiate co-operation and to support the development of structured CCs.
Our center invited 3000 physicians from Berlin and/or Brandenburg to participate. They were chosen either due to already referring patients with rare metabolic diseases to the center, residing in a neighborhood with diverse ethnic background, known to have a high prevalence for specific metabolic diseases, or working as a medical sub-specialist (gastroenterology, hematology, rheumatology) with a high probability to diagnose a rare metabolic disease. The center offered co-operation contracts, administrative and structured medical support, privileged access to the center for physicians and their patients, as well as a program of continuous medical education (CME) over a period of 12 months.
Between 0.1 to 0.5% (mean 0.2%) of the invited physicians participated in CME meetings. None of them was interested in setting up a co-operating center. The physicians were interested in broadening their knowledge about rare diseases, but less so in direct care for these patients and not at all in fulfilling the requirements of the NAP.
The requirements of the NAP for CC are thought of as unrealistic due to their demands on structural re-organization, quality measurements and additional work-load for outpatient-care. Especially so, with respect for the low number of patients profiting from these efforts and the lack of re-imbursement. We suggest a reconsideration of the German NAP.
2009 年,欧盟委员会呼吁制定国家行动计划(NAP),以改善对罕见病患者的护理。德国于 2013 年制定了 NAP,提出了合作中心(CC)、卓越中心(CE)和参考中心(CR)的三级结构。此后,CE 和 CR 就在大学附属医院的框架内组织起来。然而,考虑到 NAP 的要求,CC 的实现一直很缓慢。因此,我们制定了一个为期 12 个月的计划,以启动合作并支持结构化 CC 的发展。
我们的中心邀请了来自柏林和/或勃兰登堡的 3000 名医生参加。他们要么是因为已经将罕见代谢疾病患者转诊到中心,要么是因为居住在一个民族背景多样化的社区,要么是因为患有特定代谢疾病的高发病率,要么是因为作为一名医学亚专科医生(胃肠病学、血液学、风湿病学),有很高的可能性诊断出罕见代谢疾病而被选中。中心提供合作合同、行政和结构化医疗支持、为医生及其患者提供优先进入中心的机会,以及为期 12 个月的持续医学教育(CME)计划。
在受邀的医生中,有 0.1%至 0.5%(平均 0.2%)参加了 CME 会议。他们都对建立合作中心不感兴趣。医生们对扩大他们对罕见疾病的了解很感兴趣,但对直接照顾这些患者的兴趣较小,对满足 NAP 的要求则毫无兴趣。
NAP 对 CC 的要求被认为是不切实际的,因为它们对结构重组、质量测量和额外的门诊护理工作量提出了要求。特别是考虑到从这些努力中受益的患者数量较少,以及缺乏报销。我们建议重新考虑德国的 NAP。